<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03646955</url>
  </required_header>
  <id_info>
    <org_study_id>DBCG RT Natural Trial</org_study_id>
    <nct_id>NCT03646955</nct_id>
  </id_info>
  <brief_title>Partial Breast Versus no Irradiation for Women With Early Breast Cancer</brief_title>
  <official_title>The DBCG RT Natural Trial: Partial Breast Versus no Irradiation for Women &gt;=60 Years Operated With Breast Conservation for an Early Breast Cancer: a Clinically Controlled Randomized Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Breast Cancer Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish Center for Interventional Research in Radiation Oncology (CIRRO)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Danish Breast Cancer Cooperative Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      All early breast cancer patients are offered adjuvant breast radiation therapy (RT) after
      breast conserving surgery for an early breast cancer. Breast cancer is heterogeneous, and
      selected patients have a very low gain from RT, whilst they still have risk of acute and late
      side effects from RT. This trial will try identify selection criteria for low risk breast
      cancer patients who can safely omit adjuvant RT without unacceptable high risk of local
      failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      International standard of therapy is to provide adjuvant breast radiation therapy (RT) after
      breast conserving surgery for an early breast cancer to lower the risk of local and distant
      failures. However, breast cancer is a heterogeneous disease, and the gain from RT in selected
      low risk patients is low. RT may cause acute and late side effects, and some of these may be
      serious to the patient. Therefore, there is a need to tailor RT utilization to the individual
      recurrence risk and try identify patients who are unlikely to gain much risk reduction from
      RT, because those patients can then omit RT and thereby avoid late effects and
      over-treatment. At the present time there is no consensus as to define the selection criteria
      for patients who may omit RT.

      Based on early results from the randomized DBCG RT PBI trial, external beam 40 Gy/15 fr
      partial breast irradiation (PBI) has been standard in Denmark since April 2016 for selected
      low risk breast cancer patients. Based on results from the UK IMPORT LOW trial, the 5 yr
      local recurrence risk using this technique for PBI is 0.5%, whilst 2% for developing a new
      contralateral breast cancer.

      This trial will investigate if PBI can safely be omitted in selected low risk breast cancer
      patients without causing unacceptable high risk of local failure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2035</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2033</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Clinically controlled randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Invasive local recurrence</measure>
    <time_frame>10 years</time_frame>
    <description>Invasive local recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regional nodes recurrence</measure>
    <time_frame>10 years</time_frame>
    <description>Invasive recurrence in regional nodes of the treated breast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant failure</measure>
    <time_frame>10 years</time_frame>
    <description>Invasive recurrence from the breast cancer outside the loco-regional area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>10 years</time_frame>
    <description>Death and cause of death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">926</enrollment>
  <condition>Local Neoplasm Recurrence</condition>
  <condition>Distantly Metastatic Malignant Neoplasm</condition>
  <condition>Death</condition>
  <condition>Fibrosis Breast</condition>
  <condition>Depigmentation/Hyperpigmentation of Skin</condition>
  <condition>Telangiectasia</condition>
  <condition>Scar</condition>
  <condition>Pain</condition>
  <condition>PROMs</condition>
  <arm_group>
    <arm_group_label>Partial breast irradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>External beam irradiation 40 Gy / 15 fractions, 5 fractions per week, 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No partial breast irradiation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>No partial breast irradiation</intervention_name>
    <description>Omission of radiation therapy</description>
    <arm_group_label>Partial breast irradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Female patient &gt;=60 years

        Primary tumour characteristics by conventional histopathology

          -  unilateral and unifocal non-lobular histology grade 1-2

          -  maximum microscopic size &lt;=20mm

          -  node negative determined by sentinel node or axillary lymph node dissection

          -  estrogen receptor &gt;=10% positive

          -  HER2 negative (by IHC and/or in situ hybridization)

          -  resection margin &gt;=2 mm for invasive carcinoma and any ductal carcinoma in situ
             associated with the cancer

        Surgical type is breast conservation

        Performance status ECOG 0-2

        No evidence of distant metastasis

        Exclusion Criteria:

          -  multifocal or multicentric invasive carcinoma or ductal carcinoma in situ

          -  evidence of clinical or pathological T4 breast cancer

          -  grade 3 malignancy

          -  previous breast cancer or DCIS irrespective of disease-free interval

          -  previous radiation therapy to the breast or thorax,

          -  previous neoplasm within 5 years except carcinoma in situ of the cervix, endometrium
             or coli, melanoma in situ.

          -  comorbidity precluding the patient from radiation therapy (e.g. cardiovascular or
             pulmonary disease, scleroderma, systemic lupus erythematosus).

          -  mental/psychiatric disorder which precludes the patient from understanding the
             randomization and the follow up.

          -  documented hereditary breast cancer or with high genetic risk of breast cancer

          -  life expectancy &lt;10 years
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Birgitte V Offersen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Breast Cancer Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Birgitte V Offersen, PhD</last_name>
    <phone>+45 28838012</phone>
    <email>bvo@oncology.au.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamas Lörinz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanne M Nielsen, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus Kamby, DMSc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise W Matthiessen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Naestved Hospital</name>
      <address>
        <city>Naestved</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sami Al-Rawi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mette H Nielsen, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Troels Bechmann, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kristiansand Hospital</name>
      <address>
        <city>Kristiansand</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Unn-Miriam Kasti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital, Radiumhospitalet</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Reinertsen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavanger Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingvil Mjaaland</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tromsø University Hospital</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Egil Blix Støre</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University hospital</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Lundstedt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skånes University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Alkner</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 14, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Breast Cancer Cooperative Group</investigator_affiliation>
    <investigator_full_name>Birgitte Offersen</investigator_full_name>
    <investigator_title>Professor, PhD, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Recurrence, Local</mesh_term>
    <mesh_term>Telangiectasis</mesh_term>
    <mesh_term>Hyperpigmentation</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>When the results from the trial are published, the DBCG RT Committee can decide that the results may be part of a meta-analysis.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>It will only be possible if the DBCG Radiation Therapy Committee decides that it is acceptable</ipd_time_frame>
    <ipd_access_criteria>The DBCG Radiation Therapy Committee will define the criteria after publication of the results from the trial</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

